NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01993979,A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT),https://clinicaltrials.gov/study/NCT01993979,POUT,UNKNOWN,"POUT is a multi-centred randomised controlled phase III trial. 345 patients who have undergone nephro-ureterectomy, are surgically staged pT2-pT4, N0-3 or are pT1 and node positive, and who are fit for adjuvant chemotherapy, will be randomised to four cycles of adjuvant platinum based chemotherapy (experimental group) or surveillance (control group). Participants will be followed up according to routine practice.

Primary endpoint: Disease-free survival (DFS)

Secondary endpoints:

* Overall Survival
* Metastasis free survival
* Incidence of bladder second primary tumours
* Incidence of contralateral primary tumours
* Acute and late toxicity
* Treatment compliance
* Quality of life",NO,Transitional Cell Carcinoma of Ureter,DRUG: Chemotherapy|OTHER: Surveillance,"Disease-free survival (DFS), To determine whether adjuvant combination chemotherapy improves the disease-free survival for patients with resected histologically confirmed muscle invasive (pT2-T4, N0-3) or node positive upper tract TCC., 3 years","Overall survival, Whether adjuvant platinum-based chemotherapy improves overall survival in this patient group, Patients followed-up for 5 years|Metastasis free survival, To determine whether adjuvant platinum-based chemotherapy improves metastasis free survival in this patient group., Patients are followed up for 5 years|Incidence of bladder second primary tumours, Whether adjuvant platinum-based chemotherapy reduces incidence of second primary urothelial cancers, Patients are followed up for 5 years|Incidence of contralateral primary tumours, To determine whether adjuvant platinum-based chemotherapy reduces incidence of contralateral primary urothelial cancers., Patients are followed up for 5 years|Acute and late toxicity, To assess the toxicity of chemotherapy in this patient group., Patients are followed up for 5 years|Quality of life (QoL), To assess the relative quality of life in patients undergoing adjuvant chemotherapy or surveillance in this patient group., Patients' QoL will be assessed over 2 years",,"Institute of Cancer Research, United Kingdom",Cancer Research UK,ALL,"ADULT, OLDER_ADULT",PHASE3,261,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ICR-CTSU/2011/10031|2011-002577-33|ISRCTN98387754|CRUK/11/027|11/NW/0782,2012-05,2018-11-07,2022-05,2013-11-25,,2020-05-04,"William Harvey Hospital, Ashford-Kent, England, TN24 0LZ, United Kingdom|North Devon District Hospital, Barnstaple, England, EX31 4JB, United Kingdom|Basildon University Hospital, Basildon, England, SS16 5NL, United Kingdom|Kent and Canterbury Hospital, Canterbury, England, CT2 3NG, United Kingdom|Royal Free Hospital, Hampstead, London, England, NW3 2QG, United Kingdom|Ipswich Hospital NHS Trust, Ipswich, England, IP4 5PD, United Kingdom|St. James's University Hospital, Leeds, England, LS9 7TF, United Kingdom|Barts and the London School of Medicine, London, England, EC1M 6BQ, United Kingdom|Maidstone Hospital, Maidstone, England, ME16 9QQ, United Kingdom|Christie Hospital NHS Trust, Manchester, England, M20 4BX, United Kingdom|Queen Elizabeth The Queen Mother Hospital, Margate, England, CT9 4AN, United Kingdom|Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, CH63 4JY, United Kingdom|Nottingham City Hospital NHS Trust, Nottingham, England, NG5 1PB, United Kingdom|Peterborough Hospitals Trust, Peterborough, England, PE3 6DA, United Kingdom|Rosemere Cancer Centre at Royal Preston Hospital, Preston, England, PR2 9HT, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, England, S1O 2SJ, United Kingdom|Royal Marsden Hosital, Sutton, Surrey, England, SM2 5PT, United Kingdom|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, SS0 0RY, United Kingdom|New Cross Hospital, Wolverhampton, England, WV10 0QP, United Kingdom|Ayr Hospital, Ayr, Scotland, KA6 6DX, United Kingdom|Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, CF14 2TL, United Kingdom|Singleton Hospital, Swansea, Wales, SA 2 8QA, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Royal Marsden Hospital, Chelsea, SW3 6JJ, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|Darent Valley Hospital, Dartford, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Royal Bournemouth General Hospital, Dorset, United Kingdom|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Surrey County Hospital, Guildford, GU2 7XX, United Kingdom|Calderdale Royal Infirmary, Halifax, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, United Kingdom|Caithness General Hospital, Inverness, IV2 3UJ, United Kingdom|Raigmore Hospital, Inverness, IV2 3UJ, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, LN2 5QY, United Kingdom|Royal Liverpool University Hospital, Liverpool, L7 8XP, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom|Charing Cross Hospital, London, United Kingdom|Northwick Park Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Norfolk and Norwich University Hospital, Norwich, NR4 7UY, United Kingdom|Queen Alexandra Hospital,, Portsmouth, United Kingdom|Glan Clywd Hospital, Rhyl, LL18 5UJ, United Kingdom|Queen's Hospital,, Romford, Essex, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, SY3 8XQ, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Lister Hospital, Stevenage, SG1 4AA, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, TS19 8PE, United Kingdom|Frimley Park Hospital, Surrey, GU16 7UJ, United Kingdom|The Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom|Musgrove Park Hospital, Taunton, United Kingdom|Torbay District General Hospital, Torbay, TQ2 7AA, United Kingdom|Royal Cornwall Hospital, Treliske, TR1 3LJ, United Kingdom|Worthing Hospital, Worthing, BN11 2DH, United Kingdom|York District Hospital, York, YO31 8HE, United Kingdom",
